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Extracellular matrix metalloproteinases (MMPs) are a group of proteins that activate substrates by enzymatic cleavage and, on the
basis of their activities, have been demonstrated to play a role in ageing. Thus, in order to gain insight into the pathophysiology of
ageing and to identify new markers of longevity, we analysed the activity levels of MMP-2 and MMP-9 in association with some
relevant haematochemical parameters in a Sicilian population, including long-living individuals (LLIs, ≥95 years old). A cohort
of 154 healthy subjects (72 men and 82 women) of different ages (age range 20-112) was recruited. The cohort was divided into
five subgroups: the first group with subjects less than 40 years old, the second group ranging from 40 to 64 years old, the third
group ranging from 65 to 89 years old, the fourth group ranging from 90 to 94 years old, and the fifth group with subjects more
than 95 years old. A relationship was observed between LLIs and MMP-2, but not between LLIs and MMP-9. However, in the
LLI group, MMP-2 and MMP-9 values were significantly correlated. Furthermore, in LLIs, we found a positive correlation of
MMP-2 with the antioxidant catabolite uric acid and a negative correlation with the inflammatory marker C-reactive protein.
Finally, in LLIs MMP-9 values correlated directly both with cholesterol and with low-density lipoproteins. On the whole, our
data suggest that the observed increase of MMP-2 in LLIs might play a positive role in the attainment of longevity. This is the
first study that shows that serum activity of MMP-2 is increased in LLIs as compared to younger subjects. As far as we are
concerned, it is difficult to make wide-ranging conclusions/assumptions based on these observations in view of the relatively
small sample size of LLIs. However, this is an important starting point. Larger-scale future studies will be required to clarify
these findings including the link with other systemic inflammatory and antioxidant markers.
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1. Introduction
Ageing is a time-dependent functional decline, which
involves a progressive deterioration of organism physiologi-
cal functions heading to increased susceptibility to disease
and death. This process is unavoidable and extremely com-
plex. However, in the last 40 years, a lot of efforts have been
made to characterize ageing. As described in literature, there
are two ways to age. The first is free of age-related diseases
and without disability (successful ageing), while the latter is
characterized by a progressive tendency toward inflammage-
ing, disability, and age-related diseases (unsuccessful ageing)
[1]. Major age-related diseases include atherosclerosis, Alz-
heimer’s disease, and diabetes, where the inflammatory com-
ponents that were prolonged and persisted become damaging
[1, 2]. On the other hand, long-living individuals (LLIs) are
considered the best example of successful ageing [3].
Extracellular proteinases are a group of proteins that acti-
vate substrates by enzymatic cleavage and, on the basis of
working mechanisms, are classified into aspartic, metallo-,
cysteine, serine, and threonine proteinases [4]. Among dif-
ferent immune cells, macrophage and neutrophils are the
main responsible for matrix metalloproteinase (MMP) pro-
duction. This group of proteins controls a large variety of
key physiological and pathological processes, including tis-
sue remodelling, DNA replication, cell-cycle progression,
neurodegeneration, and cancer [5].
Moreover, MMPs are responsible for remodelling of
extracellular matrix (ECM), which represents a three-
dimensional network of extracellular macromolecules such
as collagen, enzymes, and glycoproteins, that provides struc-
tural and biochemical support of surrounding cells [6], par-
ticularly of stem cell niche [7, 8]. The perturbation of ECM
remodelling has been associated with ageing and age-
related disorders, for example, progeria (an extremely rare,
autosomal, dominant genetic disorder in which symptoms,
resembling aspects of ageing, are manifested at a very early
age) [9], arterial ageing, hypertension-associated vascular
changes [10], cancer metastasis, heart failure, and cerebral
ischemia and neurological disorders including Parkinson’s
and Alzheimer’s diseases [11, 12]. Therefore, the analysis of
MMPs can add important information to ageing process
and to longevity. As an example, ECM proteins, like elastins,
can be a good candidate as a biomarker of ageing due to low
turnover and to capacity to accumulate damage during age-
ing process [13], as in a vascular one. Also, collagen, another
ECM protein, is deeply involved in ageing since its accumu-
lation drives both vascular and lung ageing [14]. In addition,
in Caenorhabditis elegans, collagen, among other ECM pro-
teins, is influenced by the insulin/IGF-1-like signalling,
which in turn extend life span in a worm model [15].
MMP-2 (a type of gelatinase A, 72 kDa) and MMP-9 (a
type of gelatinase B, 92 kDa) are composed of 3 domains, dis-
tinguished by the presence of type II additional fibronectin
domain inserted into the catalytic domain. They are able to
degrade collagen, elastin, fibronectin, gelatin, and laminin
and have both proinflammatory and anti-inflammatory
impacts on numerous tissues [16–18]. In particular, MMP-
2 is constitutively expressed in several tissues and is regulated
by tumor necrosis factor-α under the influence of NF-κB
transcription factor [19], while redox-regulated p38 phos-
phorylation and subsequent AP-1 activation appear to be
critical for lipopolysaccharide-induced MMP-9 expression,
at least in murine macrophages [20]. MMP-2 is tightly
associated with inflammatory states such as osteoarthritis
[21, 22]; besides, MMP-2 protects from hypertensive heart
disease by suppressing the transcription and activity of 3-
hydroxy-3-methylglutaryl-CoA reductase in the early
stages of the hypertensive response [23]. Interestingly, it
was demonstrated that in atherosclerotic plaque, MMP-2
levels decreased, compared to nonatherosclerotic human tis-
sues [24], whereas MMP-9 levels increased, showing that
MMP-9 activity contributes to endothelial dysfunction [25].
MMP-9 is also implicated in lipid metabolism [26], and
in a mouse model, it plays an important role for aneurysm
formation [27, 28]. Moreover, the protein levels are detected
in the acute phase after stroke, whereas MMP-2 protein levels
were increased several days after when barrier leakage is pre-
sumably restored.
Thus, in our study, in order to gain insight into ageing,
age-related disease, and longevity, the activity levels of
MMP-2 and MMP-9 were analysed in association with some
relevant haematochemical parameters in a Sicilian population.
2. Materials and Methods
2.1. Subject Recruitment and Study Design. A cohort of 154
healthy subjects (72 men and 82 women) of different ages
(age range 20-112) was recruited. Donors were all Sicilians,
living in Western Sicily. A group of well-trained nutritionists
and physicians administered a questionnaire to collect demo-
graphic and anamnestic data of interest. Participants were
selected on the basis of their health status since none of them
had neoplastic, infective, or autoimmune diseases and none
was prescribed drugs known to interfere with immune-
inflammatory responses. Participants (or their relatives for
some LLIs) signed an informed consent before the enrol-
ment. To respect the privacy, everyone was identified with
an alphanumeric code. A database was created to handle
the collected information. The study protocol, conducted in
accordance with the Declaration of Helsinki and its amend-
ments, was approved by the Ethics Committee of Palermo
University Hospital (Nutrition and Longevity, No. 032017).
The suitability of the sample size was checked using free soft-
ware (http://ps-powerand-sample-sizecalculation.software
.informer.com) on the basis of the results of our previous
studies. The analysed cohort was divided into five subgroups:
the first group included people less than 40 years old (19%,
group 1—young people; N = 29), the second group ranging
from 40 to 64 years old (25%, group 2—adult people; N =
39), the third group ranging from 65 to 89 years old (32%,
group 3—old people; N = 50), the fourth group ranging from
90 to 94 years old (8%, group 4—oldest old people; N = 12),
and the fifth group characterized by subjects 95 or more years
old (16%, group 5—formed by LLIs; N = 24). The recruit-
ment was performed in accordance with the relevant guide-
lines and regulations.
2 Mediators of Inflammation
The recruited participants underwent vein puncture after
a fasting period of 10–12 hours. The fasting blood samples
were obtained in the morning (between 8:30 and 10 a.m.)
and were collected in serum tubes with no additives.
The following haematochemical parameters were per-
formed for all participants: albumin, alanine and aspartate
transaminases, alkaline phosphatase, bilirubin, calcium, cre-
atinine, C-reactive protein (CRP), ferritin, glycaemia, high-
density lipoproteins, iron, low-density lipoproteins (LDL),
magnesium, potassium, total cholesterol (CHO), total pro-
teins, transferrin, triglycerides, urea, and uric acid (UA) as
well as complete blood count tests. The tests were carried
out at the Department of Laboratory Medicine, “P. Giaccone”
University Hospital, Palermo, according to standard proce-
dures. In particular, CRP measurement was performed by
immunoturbidimetry methods, UA by colorimetric test,
and lipid parameters by enzymatic colorimetric test through
Roche/Hitachi Cobas system.
Table 1 shows the baseline characteristics of the studied
cohort with haematochemical parameters shown to be asso-
ciated with MMPs.
2.2. Gelatin Zymography and Polyacrylamide Gel
Electrophoresis. Serum protein concentration was quantified
spectrophotometrically, using the Bradford assay, as
described in [29, 30]. For SDS-PAGE, aliquots of 10μL of
sera, previously diluted (1 : 25), containing approximately
28μg of total proteins, were mixed with Laemmli buffer
(2% w/v SDS, 10% glycerol, 5% β-mercaptoethanol, and
62mM Tris-HCl pH6.8), boiled for 5min, and loaded on
10 × 8 cm vertical 8% polyacrylamide gel. The run was per-
formed at 150V for 50min with a Mini Protean II Xi System
(Bio-Rad Laboratories S.r.l., Milano). The running buffer was
25mM Tris-HCl, 200mM glycine, and 0.1% w/v SDS. Gels
were stained with 0.2% Coomassie Brilliant Blue G-250 in
40% methanol and 10% acetic acid and de-stained in 7%
methanol and 5% acetic acid. For zymography assay, aliquots
of 10μL of sera previously diluted (1 : 25) were loaded onto
7.5% polyacrylamide SDS-PAGE gel copolymerized with
0.1% gelatin, under nonreducing conditions, and run at
150V in a Tris-glycine buffer, as described by Cancemi et al.
[31–33]. After electrophoresis, gels were incubated at room
temperature for 1h in a wash buffer (50mM Tris-HCl
pH7.5 and 2.5% Triton X-100) to remove the SDS and then
incubated for 18h at 37°C with an activation buffer (50mM
Tris-HCl pH7.5, 150mM NaCl, and 5mM CaCl2), to allow
the activation of the gelatinases, as previously described [34,
35]. Gels were stained with Coomassie Blue. Band intensity
wasmeasured with ImageJ software. Protein samples extracted
from human breast cancer tissues [36–39] were used as refer-
ence for MMP-2 and MMP-9 activity levels. All experiments
were performed in triplicate. Gelatinolytic activity appeared
as white bands on a dark background (Figures 1(a) and 2).
2.3. Statistical Analysis. The data were processed using Graph-
Pad Prism software version 5.0 (GraphPad Software, La Jolla,
CA, United States). Nonparametric tests were applied for sta-
tistical analyses. In particular, the Mann–Whitney U test was
used to compare two subgroups of patients, and the Krus-
kal–Wallis test was used to compare three or more subgroups
of subjects. The two-tailed alpha level was set to p < 0:05 to
indicate a significant difference. The correlations were per-
formed applying the Pearson correlation test.
3. Results
3.1. Activity Levels of MMP-2 and MMP-9 in Serum Samples
and Their Correlation with Age. Sera from all subjects
enrolled in this study were subjected to gelatin zymography
to determine the relative levels of activity attributable to
MMP-2 and MMP-9. Figure 1 shows a panel of 36 zymo-
grams randomly selected among the collection of our sam-
ples. Parallel SDS polyacrylamide gels were run in order to
ascertain the correct protein loading. The two prominent
Table 1: Baseline characteristics of the studied cohort with haematochemical parameters.
n = %ð Þ Group 1 Group 2 Group 3 Group 4 Group 5
Age <40 40-64 65-89 90-94 ≥95
n = %ð Þ 154 29 (19%) 39 (25%) 50 (32%) 12 (8%) 24 (16%)
Gender
M 72 (47%) 13 (45%) 19 (49%) 28 (56%) 6 (50%) 6 (25%)
F 82 (53%) 16 (55%) 20 (51%) 22 (44%) 6 (50%) 18 (75%)
CRP
<5 g/dL 127 (82%) 26 (90%) 34 (87%) 43 (86%) 6 (50%) 18 (75%)
≥5 g/dL 27 (18%) 3 (10%) 5 (13%) 7 (14%) 6 (50%) 6 (25%)
UA
<2.4 g/dL 15 (10%) 4 (14%) 4 (10%) 1 (2%) 3 (25%) 3 (12%)
2.4-7 g/dL 114 (74%) 23 (79%) 33 (85%) 37 (74%) 3 (25%) 18 (75%)
>7 g/dL 25 (16%) 2 (7%) 2 (5%) 12 (24%) 6 (50%) 3 (13%)
CHO
<200 g/dL 113 (73%) 27 (93%) 22 (56%) 35 (70%) 10 (83%) 19 (79%)
≥200 g/dL 41 (27%) 2 (7%) 17 (44%) 15 (30%) 2 (17%) 5 (21%)
LDL
<70 g/dL 15 (10%) 5 (17%) 0 (0%) 4 (8%) 2 (17%) 4 (17%)
70-129 g/dL 106 (69%) 23 (79%) 23 (59%) 34 (68%) 8 (66%) 18 (75%)
>70 g/dL 33 (21%) 1 (4%) 16 (41%) 12 (24%) 2 (17%) 2 (8%)
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gelatinolytic bands represent the proenzymatic forms of
MMP-2 (Pro-MMP-2) (72 kDa) and of MMP-9 (Pro-
MMP-9) (92 kDa). Two additional lytic bands of 200 and
116 kDa, identified as MMP-9 dimers (220 kDa) and as
MMP-9/TIMP1 complex (116 kDa), are also evident [40,
41]. In all serum samples, no activity levels were evident
for the active forms of the MMPs.
The activity levels of Pro-MMP-9 in all samples appear
more intense than Pro-MMP-2. In order to assess the relative
variations of the two Pro-MMP levels in all subjects
(Figure 2), gels, containing samples, run in triplicate were
subjected to densitometric analysis by using the ImageJ soft-
ware, as described in Materials and Methods.
The subjects are allocated in the gels as follows: group
1—young people, N = 29: lanes 12, 44, 45, 46, 75, 77, 79, 80,
81, 82, 85, 89, 90, 92, 98, 99, 100, 106, 109, 110, 115, 118,
122, 125, 128, 130, 136, 142, and 145; group 2—adult people,
N = 39: lanes 11, 14, 15, 16, 25, 27, 33, 34, 39, 50, 52, 54, 60,
64, 66, 69, 72, 74, 78, 88, 91, 93, 95, 104, 105, 108, 116, 117,
121, 123, 124, 127, 131, 134, 135, 138, 139, 144, and 152;
group 3—old people, N = 50: lanes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
13, 17, 19, 20, 22, 23, 28, 29, 38, 42, 43, 47, 51, 55, 57, 63,
68, 76, 83, 84, 86, 87, 94, 97, 101, 102, 103, 113, 114, 119,
120, 126, 132, 137, 140, 141, 146, 149, 151, and 154; group
4—oldest old people, N = 12: lanes 31, 35, 53, 56, 58, 61, 62,
70, 71, 73, 129, 133; and group 5—LLIs, N = 24: lanes 18,
6 7 8 9 10 11 12 13 14 15
(a)
(b)
16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 361 2 3 4 5
Pro MMP-9
Pro MMP-2
Pro MMP-9/Pro MMP-9
Pro MMP-9/TIMP-1
50 kDa
60 kDa
80 kDa
110 kDa
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Figure 1: Pro-MMP-2 and Pro-MMP-9 activity levels evaluated by gelatin zymography. (a) Prototype of gelatin zymography of 36 randomly
selected serum samples used. (b) SDS-PAGE electrophoresis of the same serum samples of (a) stained with Coomassie Blue. LLIs are indicated
in (b) with asterisks.
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Figure 2: Gelatin zymography of the 154 analysed serum samples. Each lane represents a different subject. Experiments were performed in
triplicate, and the densitometric bands were quantified by using ImageJ software. St represents protein samples extracted from human breast
cancer tissues used as standard.
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21, 24, 26, 30, 32, 36, 37, 40, 41, 48, 49, 59, 65, 67, 96, 107, 111,
112, 143, 147, 148, 150, and 153.
In order to assess the possible correlations between levels
of gelatinase activity and age, a statistical analysis was per-
formed between the enzymatic activities of the different indi-
viduals divided in groups as described in Materials and
Methods. Figures 3(a) and 3(b) report an overview of the dis-
tribution of Pro-MMP-2 and Pro-MMP-9 activities over the
5 groups, corresponding to the average of three measure-
ments per sample. Although the activity levels of each Pro-
MMP are variable within the subjects, a significant associa-
tion was obtained for Pro-MMP-2 (Figure 3(b)). In particu-
lar, the Pro-MMP-2 activity levels increase with age.
Significant differences were observed between the first, sec-
ond, and third groups and the group of LLIs. No significant
differences were obtained between the fourth and the fifth
group, probably due to poor representation of the fourth
group (8%) and the age proximity with the fifth group.
In contrast, the activity levels of Pro-MMP-9
(Figure 3(a)) did not show any correlation with age. How-
ever, only in the LLI group the activity level of Pro-MMP-2
was significantly related to Pro-MMP-9 activity (r = 0:53,
p < 0:01).
Interestingly, when the cohorts were analysed according
to gender, a clear increase of Pro-MMP-2 activity with age
was observed in the male gender but not in female gender
(Figures 4(a) and 4(b)), probably because, especially in
women, the expression of MMPs is also dependent on
the hormonal status [42, 43]. Another hypothesis could
be that of the better health of male LLIs. It is known that
male centenarians are fewer in number but healthier than
women [44]. The small number studied does not allow us
to analyse this possibility. Due to the reduced size samples,
in males, the significance was only obtained between the
LLI and younger groups.
3.2. Pro-MMP-2 and Pro-MMP-9 Correlation with Some
Relevant Haematochemical Parameters. The correlation
between the serum activity levels of Pro-MMP-2 and CRP
and UA was also analysed. In fact, MMP-2 activity plays a
relevant role in tissue remodelling and in the pathophysiol-
ogy of inflammation, CRP is an inflammatory marker [45],
and serum UA is considered to have an antioxidant effect
[46]. Interestingly, a significant correlation was found only
in LLIs. In particular, we found an inverse correlation
between CRP levels and Pro-MMP-2 activity in LLIs
(r = −0:39, p < 0:05; Figure 5(a)). On the contrary, we found
a positive correlation between UA levels and Pro-MMP-2
activity in LLIs (r = 0:41, p < 0:05; Figure 5(b)).
The data in Figure 6 are depicted also according to the
gender where it is clear that in the female LLI population,
Pro-MMP-2 activity inversely correlates with CRP
(r = −0:5680, p = 0:0139) and positively correlates with UA
(p = 0:512, p = 0:0305).
Since MMP-9 modulates cholesterol metabolism [26], we
analysed the correlation between Pro-MMP-9 activity and
CHO levels. Interestingly, we found a positive correlation
between cholesterol levels and Pro-MMP-9 activity in LLIs
(r = 0:52, p < 0:001).
We also found a positive correlation between LDL levels
and Pro-MMP-9 activity in LLIs (r = 0:43, p < 0:05;
Figures 7(a) and 7(b)).
The data in Figure 8 show the same results according to
gender. In the male LLI population, Pro-MMP-9 activity cor-
relates positively with CHO (r = 0:81, p = 0:0479) and with
LDL (p = 0:77, p = 0:049).
4. Discussion
In the present study, the possible role played by MMPs in
ageing and longevity has been focused. MMPs are a family
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Figure 3: Box plot graphs of Pro-MMP-9 (a) and Pro-MMP-2 (b) activity levels evaluated by gelatin zymography grouped for age. The ends
of the box are the upper and lower quartiles, the lines extending parallel from the boxes are used to indicate variability outside the upper and
lower quartiles while the median is marked by a vertical line inside the box. The densitometric analysis, performed by measuring the intensity
levels of each band and the corresponding area, is referred as volume. Statistical analysis was performed applying the Kruskal–Wallis
nonparametric test. ∗p < 0:05, ∗∗p < 0:01, and ∗∗∗p < 0:001.
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of structurally and functionally related zinc-dependent pro-
teases with a wide range of substrates, including ECM com-
ponents, cytokines, receptors, and cell motility factors. It is
widely recognized that MMPs play a role in the pathophysi-
ology of various tissues during growth, development, and
ageing. Traditionally, the gelatinase members of the MMP
family, MMP-2 and MMP-9, have been the easiest to detect
using gelatin zymography; therefore, there are much more
available data on them [47–49].
Previous studies demonstrated that ageing is associated
with increased activities of MMP-2 [50] or of MMP-2 and
MMP-9 [51] and concentration of active MMP-9 decreases
with age [48].
Many studies on ageing showed that LLIs are the best
models of ageing with success, so this old population is the
best population to be studied. On the average of onset of
age-associated diseases, centenarians have been divided into
three profiles, survivors, delayers, and escapers. Survivors
had a diagnosis of an age-associated disease prior to the age
of 80. Delayers were affected by an age-associated disease
after the age of 80. Escapers attained 100th year of life without
the diagnosis of age-associated diseases [52]. Therefore, the
extreme longevity is often characterized by a not unique
and unequivocal phenotype, because there may be multiple
routes to achieve exceptional longevity. However, each LLI
can represent a model of “positive biology” by which it
is possible to explain the biological mechanisms of health
and well-being [44].
Changes associated with ageing affect the immune-
inflammatory responses as shown by decline in immune
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Figure 5: Histograms of Pro-MMP-2 activity levels in the LLI group and hematological values of CRP (a) and UA (b) to show the found
correlations. The trend of the line in hematological parameters shows a positive or inverse correlation.
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Figure 4: Scatter plot graphs of Pro-MMP-2 activity levels in female (a) and male (b) evaluated by gelatin zymography and grouped for age.
The lines indicate mean and standard error. The densitometric analysis, performed by measuring the intensity levels of each band and the
corresponding area, is referred as volume. Statistical analysis was performed applying the Kruskal–Wallis nonparametric test. ∗∗∗p < 0:001.
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function and increase in the systemic proinflammatory sta-
tus, i.e., immunosenescence, linked not only to the functional
decline associated with the passage of time but also to antigen
burden to which an individual has been exposed during life-
time [53]. The long-life chronic antigenic stress contributes
to the chronic state of low-grade inflammation, inflammage-
ing, observed in old people. Inflammageing is characterized
by an increase in the levels of proinflammatory mediators.
That, in turn, represents a negative prognostic factor for all
causes of death. Oxidative stress plays an important role in
determining and maintaining low-grade inflammation,
which contributes to oxidative stress [54]. So, centenarians
show an increase in many inflammatory molecules compar-
ing to adults, but this condition is compensated by a concom-
itant activation of anti-inflammatory responses. This
suggests that inflammageing may coexist with longevity
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Figure 6: Histograms of Pro-MMP-2 activity levels in the LLI group and hematological values of CRP (a, b) and UA (c, d) in female (a–c) and
in male (b–d) to show the found correlations. The trend of the line in hematological parameters shows a positive or inverse correlation.
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Figure 7: Histograms of Pro-MMP-9 (a, b) activity levels in the LLI group and hematological values of CHO (a) and LDL (b) to show the
found correlations. The trend of the line in hematological parameters shows a positive correlation for both.
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especially if counterbalanced by an anti-inflammatory com-
ponent. Someone who will (probably) become a centenarian
should be able to keep inflammation down for longer [44].
The knowledge coming from these studies might provide
valuable information to achieve healthy ageing by modulat-
ing the ageing rate and pointing out a sort of longevity signa-
ture. The identification of the factors that predispose to a
successful ageing is of enormous interest for translational
medicine [3].
In our paper, the results show that serum activity of
MMP-2 increases in LLIs as compared to younger subjects.
Furthermore, in LLIs, we find a positive correlation of
MMP-2 with UA and an inverse correlation with CRP.
UA is the end product of endogenous and exogenous
purine metabolism, and some epidemiological studies sug-
gest that increased serum levels of UA are a risk factor for
diseases where oxidative stress plays an important role. On
the contrary, other evidence shows that UA might play a role
as an antioxidant [46]. The possible explanation lies in the
fact that UA might behave as oxidant getting older.
CRP, primarily secreted by the liver, is the most impor-
tant biomarker of inflammation, commonly evaluated for
monitoring treatment response and predicting long-term
outcome in inflammatory diseases. The serum levels of CRP
increase in an age-dependent manner and are good predic-
tors of physical and cognitive performance and of the risk
of mortality in both the entire old population and in success-
fully aged individuals [45].
Despite their name, MMP enzymes are not just bulk
degraders of matrix proteins but they also provide a mecha-
nism to add an additional layer of regulation to intercellular
communication, including inflammation. In particular,
MMP-2 regulates the processing of the chemokine
monocyte-chemotactic protein 3 generating a chemokine
receptor antagonist, which, in turn, might provide a regula-
tion of the inflammatory signalling cascades directly exerted
by MMP-2 [55]. More interestingly, MMP-2 activation is
responsible for degrading the alarmin S100A9, thus limiting
inflammation-inducing signals. It is relevant that alarmins
are mediators of sterile inflammation in ageing and age-
related diseases [56].
Therefore, the anti-inflammatory activity of MMP-2 can
explain the negative and positive associations, respectively,
with CRP and UA as well as the increased level in LLIs when
compared to other younger groups. However, a note of cau-
tion in the interpretation of these results should be added
because it has been demonstrated that antihypertensive drugs
may reduce Pro-MMP-2 activity [57] and we do not have this
information for most subjects under study.
MMP9 affects cholesterol metabolism, at least in part,
through a MMP-9 plasma-secreted phospholipase A2 axis
that affects the hepatic transcriptional responses to dietary
cholesterol. Therefore, it has been proposed that the dysreg-
ulation of MMP-9 can contribute to the development of met-
abolic disorders that could, ultimately, lead to atherosclerosis
and coronary heart disease [26]. The MMP-9 results show
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Figure 8: Histograms of Pro-MMP-9 activity levels and hematological values of CHO in the female (a) and male (b) LLI group and of LDL in
the female (c) and male (d) LLI group.
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that their levels do not increase in LLIs and that the levels are
highly variable in the whole population.
On the whole, the observed increase of MMP-2 in LLIs
might suggest a positive role in the attainment of longevity.
Interestingly, MMPs have been characterized as bifunctional
proteins in Alzheimer’s disease, with some of them, such as
MMP-2 and MMP-9, displaying protective roles during dis-
ease progression, while others promote disease evolution [7].
However, it is difficult to make wide-ranging conclusion-
s/assumptions based on these observations in view of the rel-
atively small sample size of LLIs. Nonetheless, we believe that
this is an important starting point for future larger-scale
studies required to warrant these findings including the link
with other systemic inflammatory and antioxidant markers.
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